Peripartum care of the cocaine-abusing parturient: Are we ready?

Acta Obstetricia et Gynecologica Scandinavica

Volumn 84, Issue 2, 2005, Pages 108-116

  Kuczkowski, Krzysztof M ^a,b  

^a School of Medicine   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Analgesia; Cardiovascular; Chest pain; Cocaine; Dysrhythmias; Infarction; Ischemia; Labor; Pregnancy; Toxicity; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ATENOLOL; ATROPINE; BENZODIAZEPINE DERIVATIVE; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COCAINE; DILTIAZEM; ESMOLOL; GLYCERYL TRINITRATE; HYDRALAZINE; INHALATION ANESTHETIC AGENT; KETAMINE; LABETALOL; LIDOCAINE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITROPRUSSIDE SODIUM; PHENTOLAMINE; PROPRANOLOL; SUXAMETHONIUM; UNINDEXED DRUG; VERAPAMIL;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; BLOOD BRAIN BARRIER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COCAINE DEPENDENCE; CORONARY ARTERY CONSTRICTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; FEMALE; FETUS OUTCOME; FIBRINOLYTIC THERAPY; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; INTOXICATION; MATERNAL CARE; PATHOPHYSIOLOGY; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; THORAX PAIN; UNITED STATES; VASODILATATION;

ANTIDOTES; COCAINE-RELATED DISORDERS; FEMALE; FETAL DEATH; FETAL DEVELOPMENT; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PERINATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; RISK ASSESSMENT;

EID: 14044252755     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2005.00487.x     Document Type: Review

References (74)

1. Hahn IH, Hoffman RS. Cocaine use and acute myocardial infarction. Emerg Med Clin North Am 2001; 19: 493-510.
2. Kuczkowski KM. Cocaine abuse in pregnancy - anesthetic implications. Int J Obstet Anesth 2002; 11: 204-10.
3. Birnbach DJ. Anesthetic management of the drug-abusing parturient: are you ready? J Clin Anesth 2003; 15: 325-7.
4. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol 2003; 101: 374-9.
5. Kounis NG, Zavras GM, Papadaki PJ, Soufras GD, Kitrou MP, Poulos EA. Pregnancy-induced increase of supraventricular arrhythmias in Wolff-Parkinson-White syndrome. Clin Cardiol 1995; 18: 137-40.
6. Vasica G, Tennant CC. Cocaine use and cardiovascular complications. Med J Aust 2002; 177: 260-2.
7. Chakko S. Arrhythmias associated with cocaine abuse. Cardiac Electrophysiol Rev 2002; 6: 168-9.
8. Kerns W, Garvey L, Owens J. Cocaine-induced wide complex dysrhythmia. J Emerg Med 1997; 15: 321-9.
9. Birnbach DJ, Browne IM, Kim A et al. Identification of polysubstance abuse in the parturient. Br J Anaesth 2001; 87: 488-90.
10. Towers CV, Pircon RA, Nagoette MP et al. Cocaine intoxication presenting as pre-eclampsia. Obstet Gynecol 1993; 81: 545-7.
11. Kuczkowski KM. Anesthetic implications of drug abuse in pregnancy. J Clin Anesth 2003; 15: 382-94.
12. American College of Obstetricians and Gynecologists. Committee Opinion on Obstetrics: Maternal and Fetal Medicine. Cocaine in Pregnancy ACOG Committee Opinion No: 114. Washington, DC: ACOG, 1992
13. Newman LM. The chemically dependent parturient. Semin Anesth 1992; 11: 66-75.
14. Kuczkowski KM. Labor analgesia for the drug abusing parturient: is there cause for concern? Obstet Gynecol Surv 2003; 58: 599-608.
15. Birnbach DJ. Substance abuse. In: Chestnut DH, ed. Obstetric Anesthesia - Principles and Practice. St Louis: Mosby, 1999: 1027-40.
16. Kreek MJ. Cocaine, dopamine and the endogenous opioid system. J Addictive Dis 1996; 15: 73-96.
17. Vertommen JD, Hughes SC, Rosen MA et al. Hydralazine does not restore uterine blood flow during cocaine-induced hypertension in the pregnant ewe. Anesthesiology 1992; 76: 580-7.
18. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345: 351-8.
19. Kuczkowski KM. Caesarean section in a cocaine-intoxicated parturient: regional vs. general anaesthesia? Anaesthesia 2003; 58: 1042-3.
20. Hughes SC, Vertommen JD, Rosen MA et al. Cocaine induced hypertension in the ewe and response to treatment with labetalol. Anesthesiology 1991; 77: 1075.
21. Gay GR, Loper KA. The use of labetalol in the management of cocaine crisis. Ann Emerg Med 1988; 17: 282-3.
22. Hollander JE. The management of cocaine-associated myocardial ischemia. N Eng J Med 1995; 333: 1267-71.
23. Derlet RW, Tseng CC, Albertson TE. Cocaine toxicity and the calcium channel blockers nifedipine and nimodipine in rats. J Emerg Med 1994; 12: 1-4.
24. Boylan JF, Cheng DC, Sandler AN et al. Cocaine toxicity and isoflurane anesthesia: hemodynamic, myocardial metabolic, and regional blood flow effects in swine. J Cardiothorac Vasc Anesth 1996; 10: 772-7.
25. Murphy JL. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anesth 1993; 40: 160-4.
26. Birnbach DJ. Anesthesia and maternal substance abuse. In: Norris MC, ed. Obstetric Anesthesia. Philadelphia: Lippincott Williams & Wilkins, 1999: 491-9.
27. Shih RD, Hollander JE, Burstein JL et al. Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction. Ann Emerg Med 1995; 26: 702-6.
28. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. 8. Advanced challenges in resuscitation. 2. Toxicology in ECC. Circulation 2000; 102 (Suppl I): 223-8.
29. Williams RG, Kavanagh KM, Teo KK. Pathophysiology and treatment of cocaine toxicity: implications for the heart and cardiovascular system. Can J Cardiol 1996; 12: 1295-301.
30. Pitts WR, Lange RA, Cigarroa JE et al. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Prog Cardiovasc Dis 1997; 40: 65-76.
31. Mendelson JH, Mello NK. Management of cocaine abuse and dependence. N Engl J Med 1996; 334: 965-72.
32. Billman GE. The effect of adrenergic receptor antagonists on cocaine-induced ventricular fibrillation: alpha but not beta adrenergic receptor antagonists prevent malignant arrhythmias independent of heart rate. J Pharmacol Exp Ther 1994; 269: 409-16.
33. Sabra R, Khoury HA, Bechara G et al. Post-junctional mechanisms involved in the potentiation of cardiac adrenergic responses by cocaine. Eur J Pharmacol 2000; 397: 139-50.
34. Lange RA, Cigarroa RG, Yancy CW et al. Cocaine-induced coronary artery vasoconstriction. N Engl J Med 1989; 321: 1557-62.
35. Knuepfer MM. Cardiovascular disorders associated with cocaine use: myths and truths. Pharmacol Ther 2003; 97: 181-222.
36. Walsh M, Atwood J. Cocaine, pulmonary edema, and propranolol. Ann Intern Med 1989; 110: 843-4.
37. Lange RA, Cigarroa RG, Flores ED et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112: 897-903.
38. Shannon RP, Manders WT, Shen Y. Role of blood doping in the coronary vasoconstriction response to cocaine. Circulation 1995; 92: 96-105.
39. Schindler CW, Tella SR, Goldberg SR. Adrenoreceptor mechanisms in the cardiovascular effects of cocaine in conscious squirrel monkeys. Life Sci 1992; 51: 653-60.
40. Kenny D, Pagel PS, Warltier DC. Attenuation of the systemic and coronary hemodynamic effects of cocaine in conscious dogs: propranolol versus labetalol. Basic Res Cardiol 1992; 67: 1178-85.
41. Shannon RP, Stambler BS, Komamura K et al. Cholinergic modulation of the coronary vasoconstriction induced by cocaine in conscious dogs. Circulation 1993; 87: 939-49.
42. Branch CA, Knuepfer MM. Causes of differential cardiovascular sensitivity to cocaine. I. Studies in conscious rats. J Pharmacol Exp Ther 1994; 269: 674-83.
43. Knuepfer MM, Gan Q, Mueller PJ. Mechanisms of hemodynamic responses to cocaine in conscious rats. J Cardiovasc Pharmacol 1998; 31: 391-9.
44. Boehrer JD, Moliterno DJ, Willard JE et al. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993; 94: 608-10.
45. Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol 1995; 25: 113-32.
46. Negus BH, Willard JE, Hillis LD et al. Alleviation of cocaine-induced coronary vasoconstriction with intravenous verapamil. Am J Cardiol 1994; 73: 510-13.
47. Spivey WH, Euerle B. Neurologic complications of cocaine abuse. Ann Emerg Med 1990; 19: 1422-8.
48. Isner JP, Chokshi SK. Cardiac complications of cocaine abuse. Ann Rev Med 1991; 42: 133-8.
49. Wilkerson RD. Cardiovascular effects of cocaine: enhancement by yohimbine and atropine. J Pharmacol Exp Ther 1989; 248: 57-61.
50. Miao L, Qui Z, Morgan JP. Cholinergic stimulation modulates negative inotropic effect of cocaine on ferret ventricular myocardium. Am J Physiol 1996; 270: 678-84.
51. Jatlow P, Barash PG, Van Dyke C et al. Cocaine and succinylcholine sensitivity: a new caution. Anesth Analg 1988; 58: 235-8.
52. Hoffman RS, Morasco R, Goldfrank LR. Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. J Toxicol Clin Toxicol 1996; 34: 259-66.
53. Kambam J, Mets B, Hickman R et al. The effects of inhibition of plasma cholinesterase activity on systemic toxicity and blood catecholamine levels from cocaine infusion in pigs. J Lab Clin Med 1993; 122: 188-96.
54. Zimring HJ, Fitzgerald RL, Engler RL, Ito BR. Intracoronary versus intravenous effects of cocaine on coronary flow and ventricular function. Circulation 1994; 89: 1819-28.
55. Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrhythmias after massive cocaine ingestion. J Electrocardiol 2001; 34: 345-9.
56. Brogan WC, Lange RA, Kim AS et al. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. J Am Coll Cardiol 1991; 18: 581-6.
57. Gowda RM, Khan IA, Mehta NJ et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int J Cardiol 2003; 88: 129-33.
58. Jones CT, Ritchie JW. The effects of adrenergic blockade on fetal response to hypoxia. J Dev Physiol 1983; 5: 211-22.
59. Giussani DA, Riquelme RA, Sanhueza EM, Hanson MA, Blanco CE, Llanos AJ. Adrenergic and vasopressinergic contributions to the cardiovascular response to acute hypoxaemia in the llama fetus. J Physiol 1999; 15: 233-41.
60. Martin CB Jr, de Haan J, van der Wildt B, Jongsma HW, Dieleman A, Arts TH. Mechanisms of late decelerations in the fetal heart rate. A study with autonomie blocking agents in fetal lambs. Eur J Obstet Gynecol Reprod Biol 1979; 9: 361-73.
61. Eisenach JC, Castro MI. Maternally administered esmolol produces fetal beta-adrenergic blockade and hypoxemia in sheep. Anesthesiology 1989; 71: 718-22.
62. Larson CP, Shuer LM, Cohen SE. Maternally administered esmolol decreases fetal as well as maternal heart rate. J Clin Anesth 1990; 2: 427-9.
63. Ostman PL, Chestnut DH, Robillard JE, Weiner CP, Hdez MJ. Transplacental passage and hemodynamic effects of esmolol in the gravid ewe. Anesthesiology 1988; 69: 738-41.
64. Viinikka L, Ylikorkala O. Beta-blockers inhibit fetal thromboxane A2 production in vitro. Biol Neonate 1988; 54: 169-72.
65. Bjorksten B, Finnstrom O, Wichman K. Intrauterine exposure to the beta-adrenergic receptor-blocking agent metoprolol and allergy. Int Arch Allergy Appl Immunol 1988; 87: 59-62.
66. Princzkel E, Vojcek L, Lampe LG, Turnbull AC. The redistribution of the blood flow under nifedipine treatment in the sheep foetuses. Acta Paediatr Hung 1991; 31: 321-36.
67. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002; 53: 39-49.
68. Silva FR, Palermo-Neto J. Developmental, neuro and immunotoxic effects of perinatal diazepam treatment in rats. Immunopharmacol Immunotoxicol 1999; 21: 247-65.
69. Niebyl JR. Nonanesthetic drug during pregnancy and lactation. In: Chestnut DH, ed. Obstetric Anesthesia: Principles and Practice, 2nd edn. St Louis: Mosby, 1999: 235-48.
70. Caspi E, Ron-El R, Modai D. Controlled intravenous bicarbonate and fetal-maternal acid-base balance. I. The primipara. Obstet Gynecol 1979; 54: 615-23.
71. Khedun SM, Maharaj B, Moodley J. Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing? Paediatr Drugs 2000; 2: 419-36.
72. Skarsgard ED, VanderWall KJ, Morris JA, Roman C, Heymann MA, Harrison MR. Effects of nitroglycerin and indomethacin on fetal-maternal circulation and on fetal cerebral blood flow and metabolism in sheep. Am J Obstet Gynecol 1999; 181: 440-5.
73. Curry SC, Carlton MW, Raschke RA. Prevention of fetal and maternal cyanide toxicity from nitroprusside with coinfusion of sodium thiosulfate in gravid ewes. Anesth Analg 1997; 84: 1121-6.
74. Omar HA, Rhodes LA, Ramirez R, Arsich J, Einzig S. Alteration of human placental vascular tone by antiarrhythmic medications in vitro. J Cardiovasc Electrophysiol 1996; 7: 1197-203.